跳至主要内容
临床试验/NCT05272410
NCT05272410Unknown不适用

Cost-effectiveness of Strategies to Control the Spread of Carbapenemase-producing Enterobacteriaceae (CPE) in Hospitals

Assistance Publique - Hôpitaux de Paris0 个研究点目标入组 1,800 人开始时间: 2022年3月最近更新:
适应症

试验速览

阶段
不适用
入组人数
1,800
主要终点
ICER- the ratio of the difference in costs to difference in health benefits

研究概览

简要总结

Spread of extensively drug-resistant bacteria (XDR) such as carbapenemase-producing Enterobacterales (CPE) is a major public health problem. Various prevention and control interventions are implemented to limit the transmission of XDR but they are expensive and often disrupt hospital organization. In this study, a mathematical model will be used to study the effectiveness and cost-effectiveness of control strategies to limit the spread of CPE in a general hospital ward. A case-control study will be conducted to estimate the excess length of stay and mortality attributable to CPE colonisation or infection.

详细描述

Carbapenemase-producing Enterobacterales (CPE) are increasingly common in hospitals and represent a serious health problem. These multidrug-resistant organisms colonise the gastrointestinal tract after direct (person-to-person) or indirect (via contaminated surfaces) transmission and are a common cause of urinary tract infections, ventilator-associated pneumonia and bloodstream infections in healthcare settings. Treatment options for patients infected with CPE are limited leading to high mortality, increased length of hospital stay and hospital costs. The successful implementation of cost-effective infection control measures to prevent CPE spread and infections is key for infection control preventionists and hospital managers.

Recommendations to limit the transmission of CPE in healthcare facilities are based on the early detection of asymptomatic carriers, implementation of contact precautions and isolation in single room. In practice, strategies combining various interventions are employed according to the risk assessment and available resources: 1) universal or targeted rectal screening on admission, 2) standard precautions (SP), applied to all patients regardless of their infectious status, 3) contact precautions (CP) for identified carriers or infected patients, 4) isolation in a single room, 5) environmental cleaning, 6) rectal screening of contact patients, i.e. those whose care was provided by the same team as the CPE patient, and/or 7) isolation of carriers in a dedicated area with dedicated nursing staff (DNS), thereafter designated as cohorting.

However, these control measures pose challenges such as the high cost of patient's screening and cohorting, requirement for single room isolation or staff shortage for implementing precautions. Moreover, the effectiveness and cost-effectiveness of various CPE control strategies is under-documented.

OBJECTIVES:

Primary:

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients infected with emerging highly resistant bacteria at acute care hospital.

排除标准

  • patients infected while hospitalized in intensive care unit.

结局指标

主要结局

ICER- the ratio of the difference in costs to difference in health benefits

时间窗: 12 months

The incremental cost-effectiveness ratios (ICER) calculated as the extra annual cost of one strategy relative to another divided by CPE cases avoided by that strategy relative to the other strategy

次要结局

  • Costs of strategies(6 months after the end of the data collection)
  • Number of days when hospital admissions interrupted(6 months after the end of the data collection)
  • Number of days when hospital transfers interrupted(6 months after the end of the data collection)
  • frequency of employment of dedicated staff(6 months after the end of the data collection)
  • length of hospital stay of patients(6 months after the end of the data collection)
  • Number of CPE acquisitions(6 months after the end of the data collection)
  • risk of death(6 months after the end of the data collection)

研究者

申办方类型
Other
责任方
Sponsor

相似试验